39 completed, 18 recruiting, 15 not yet recruiting, 6 active not recruiting. 22 Phase 2, 19 Not applicable, 18 Phase 1, 14 Phase 3, 2 Phase 4.
Follow Atopic Dermatitis (AD): new trials by email Literature Review of Atopic Dermatitis (AD) trials Research Report on Atopic Dermatitis (AD)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Secondary Bacterial Infections and Nasal Colonization in Scabies and Atopic Dermatitis Atopic Dermatitis (AD), Scabies | Not yet recruiting | Istanbul Medeniyet University | 51 | 2026-10-01 | 2026-09-15 | |
| A Study of JYP0066 Cream in Mild-to-Moderate Atopic Dermatitis JYP0066 4% topical cream, 3% JYP0066 topical cream, 2% JYP0066 topical cream - Atopic Dermatitis (AD) | Phase 2 | Not yet recruiting | Guangzhou JOYO Pharma Co., Ltd | 160 | 2026-09-30 | 2026-09-30 |
| Study of HXN6005 in Healthy Participants and Patients With Moderate-to-Severe Atopic Dermatitis HXN6005, Placebo - Health Adult Subjects, Atopic Dermatitis (AD) | Phase 1 / Phase 2 | Not yet recruiting | Helixon Biotechnology (Suzhou) Co., Ltd | 67 | 2026-09-01 | 2026-08-24 |
| PRA-216 Atopic Dermatitis Safety and Efficacy Study Active PRA-216, Placebo - Atopic Dermatitis (AD) | Phase 2 | Not yet recruiting | Prana Therapies Inc | 39 | 2026-09-01 | 2026-09-09 |
| A Study to Evaluate the Efficacy, Safety, and Pharmacokinetic Profiles of TLL-018 in Patients With Moderate-to-Severe Atopic Dermatitis TLL-018 tablets, Placebo - Atopic Dermatitis (AD) | Phase 2 / Phase 3 | Not yet recruiting | Hangzhou Highlightll Pharmaceutical Co., Ltd | 390 | 2026-08-31 | 2026-08-25 |
| Reflectance Confocal Microscopy Evaluation of Skin Structure of Patients With Atopic Dermatitis Under Nemolizumab Atopic Dermatitis (AD), Atopic Dermatitis (Eczema) | Recruiting | Hôpitaux Drôme Nord | 15 | 2026-06-11 | 2026-07-28 | |
| A Study of Stapokibart Injection in Patients With Atopic Dermatitis (AD) Stapokibart - Atopic Dermatitis (AD) | Recruiting | Chengdu Kangnuoxing Biopharma,Inc. | 1000 | 2026-06-02 | 2026-06-10 | |
| Study of S-4321 in Participants With an Autoimmune or Immune-mediated Disease S-4321 - Autoimmune Diseases, Rheumatoid Arthritis (RA) | Phase 1 | Recruiting | Seismic Therapeutic AU Pty Ltd | 24 | 2026-06-01 | 2026-06-01 |
| Crisaborole 2% Versus Tacrolimus 0.1% in Children With Mild to Moderate Atopic Dermatitis Crisaborole 2%, Tacrolimus 0.1% - Atopic Dermatitis, Atopic Dermatitis (AD) | Phase 3 | Not yet recruiting | Shalamar Institute of Health Sciences | 66 | 2026-06-01 | 2025-09-09 |
| The Safety and Efficacy of Upadacitinib in Refractory Autoimmune Related Cholangitis and Atopic Dermatitis With Moderate to Severe Itching Upadacitinib 15 MG - Primary Biliary Cholangitis (PBC), Primary Sclerosing Cholangitis (PSC) | Phase 2 | Not yet recruiting | RenJi Hospital | 44 | 2026-06-01 | 2026-07-01 |
| Atopic Dermatitis Treated With Dupilumab and JAK Inhibitors in Costa Rica Abrocitinib, Upadacitinib, Baricitinib - Atopic Dermatitis, Atopic Dermatitis (AD) | Not yet recruiting | Caja Costarricense de Seguro Social | 50 | 2026-05-01 | 2026-04-08 | |
| Topical Chinese Medicine and Exosome Mechanisms for Atopic Dermatitis menthol-based hand and foot gloves, Sham menthol-based hand and foot gloves - Atopic Dermatitis (AD) | Phase 2 | Active not recruiting | Taiwan Municipal An-Nan Hospital-China Medical University | 44 | 2026-04-29 | 2026-07-09 |
| A Study on the Efficacy of 2% Cholesterol Cream in Atopic Dermatitis Topical 2% cholesterol cream, Placebo Vehicle Cream - Atopic Dermatitis (AD), Cholesterol | Not applicable | Enrolling by invitation | Institute of Dermatology, Thailand | 30 | 2026-04-01 | 2026-05-14 |
| Efficacy and Safety of Switching to Ivarmacitinib in Patients With Moderate-to-Severe Atopic Dermatitis With Inadequate Response to Interleukin-4 Receptor Alpha(IL-4Rα) Inhibitors: A Prospective, Multicenter, Real-World Study Ivarmacitinib Sulfate Tablets - Atopic Dermatitis (AD) | Not applicable | Not yet recruiting | Peking University People's Hospital | 300 | 2026-03-31 | 2026-04-24 |
| A Phase 1 Clinical Study Comparing GS101 and Dupixent® After Subcutaneous Injection GS101 injection, U.S. commercial Dupixent®, CN commercial Dupixent® - Atopic Dermatitis (AD) | Phase 1 | Completed | Jiangsu Genscend Biopharmaceutical Co., Ltd | 294 | 2026-03-05 | 2026-10-15 |
| Ph 1a/1b Single Ascending Dose and Multiple Ascending Dose Study of ARQ-234 ARQ-234, Placebo - Atopic Dermatitis (AD), Eczema | Phase 1 | Recruiting | Arcutis Biotherapeutics, Inc. | 125 | 2026-03-02 | 2026-10-05 |
| Efficacy of Crisaborole 2% Cream Versus Placebo in Mild to Moderate Atopic Eczema Placebo Cream, Crisaborole 2% Cream - Atopic Dermatitis (AD), Atopic Eczema | Phase 4 | Not yet recruiting | Jinnah Postgraduate Medical Centre | 270 | 2026-03-01 | 2026-03-06 |
| A Phase III Study of GS101 Injection to Dupixent® GS101 injection, DUPIXENT® - Atopic Dermatitis (AD) | Phase 3 | Recruiting | Jiangsu Genscend Biopharmaceutical Co., Ltd | 572 | 2026-01-29 | 2026-10-15 |
| Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis ENV-294, Placebo - Atopic Dermatitis (AD) | Phase 2 | Recruiting | Enveda Therapeutics | 105 | 2025-12-22 | 2026-09-25 |
| A Long-term Safety and Efficacy Study Evaluating CM512 in Atopic Dermatitis. CM512 - Atopic Dermatitis (AD) | Phase 2 | Recruiting | Keymed Biosciences Co.Ltd | 246 | 2025-12-01 | 2025-11-17 |
Showing 20 of 83. Sign in to see all of them.
Dermatitis, Atopic (83) · Eczema (18) · Pruritus (7) · Psoriasis (4) · Arthritis, Psoriatic (2) · Arthritis, Rheumatoid (2) · Dermatitis (2) · Abscess (1) · Acne Vulgaris (1) · Angioedema (1) · Asthma (1) · Autoimmune Diseases (1) · Bile Duct Diseases (1) · Biliary Tract Diseases (1) · Cholangitis (1)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (83) · Genetic Diseases, Inborn (83) · Hypersensitivity (83) · Immune System Diseases (83) · Skin and Connective Tissue Diseases (83) · Hypersensitivity, Immediate (82) · Skin Diseases (82) · Skin Diseases, Eczematous (82) · Skin Diseases, Genetic (82) · Dermatitis (81) · Pathological Conditions, Signs and Symptoms (7) · Signs and Symptoms (7) · Skin Manifestations (7) · Skin Diseases, Papulosquamous (5) · Arthritis (2)
difamilast (5) · dupilumab (5) · upadacitinib (3) · GS 101 (2) · ivarmacitinib (2) · tofacitinib (2) · Emollients (1) · Nonprescription Drugs (1) · Ointments (1) · Therapeutics (1) · Trail Making Test (1) · abrocitinib (1) · baricitinib (1) · caseinomacropeptide (1) · crisaborole (1)
AbbVie (4) · Pierre Fabre Dermo Cosmetique (4) · National Institute of Allergy and Infectious Diseases (NIAID) (3) · Otsuka Pharmaceutical Co., Ltd. (3) · Attovia Therapeutics Inc (2) · CAGE Bio Inc. (2) · Enveda Therapeutics (2) · Hôpitaux Drôme Nord (2) · Jiangsu Genscend Biopharmaceutical Co., Ltd (2) · Minghui Pharmaceutical (Hangzhou) Ltd (2) · Otsuka Beijing Research Institute (2) · Regeneron Pharmaceuticals (2) · Alphyn Biologics (1) · Arcutis Biotherapeutics, Inc. (1) · Bluefin Biomedicine, Inc. (1)
China (23) · United States (18) · Australia (7) · Canada (7) · Spain (5) · New Zealand (4) · Poland (4) · France (3) · Japan (3) · Taiwan (3) · Belgium (2) · Germany (2) · Mauritius (2) · Brazil (1) · Bulgaria (1)
Nobuhito Sanada (2) · Amisha Parikh-Das, Ph.D. (1) · Ben Snyder, Dr (1) · Brett Angel, MD (1) · Chavalit Supsrisunjai, MD, PhD (1) · Daniel Hogan, M.D. (1) · Daniel Kaplan, MD, PhD (1) · David Berk, MD (1) · Donald Leung, M.D., Ph.D. (1) · Eric Sicard, MD (1) · Ethlynn Schorr, M.D. (1) · Eva M Salinas, PhD (1)
PMID 30194992, PMID 31252032, PMID 32896640, PMID 33619370, PMID 39075274, PMID 41171590, PMID 42201487, PMID 42215271
U19AI117673 (1)